XOSL
GENT
Market cap63mUSD
Jul 28, Last price
40.00NOK
1D
0.50%
1Q
-1.48%
Jan 2017
-24.53%
IPO
42.86%
Name
Gentian Diagnostics ASA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.
Valuation
Title NOK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||